Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT00642603

Public ClinicalTrials.gov record NCT00642603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 2-weekly cycles of treatment with either: 1) Xeloda, Avastin and oxaliplatin; or 2) Xeloda, Avastin and irinotecan. After 9 cycles, patients continued to receive maintenance treatment with Xeloda + Avastin. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.

Study identification

NCT ID
NCT00642603
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
41 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2008 (Type not available)
Primary completion
Mar 2009 (Actual)
Completion
Mar 2009 (Actual)
Last update posted
Aug 26, 2026

2008 – 2009

United States locations

U.S. sites
76
U.S. states
28
U.S. cities
71
Facility City State ZIP Site status
Not listed PARK Springs Arizona 71913 —
Not listed Sedona Arizona 86336 —
Not listed Tucson Arizona 85712 —
Not listed Anaheim California 92801 —
Not listed Colton California 92324 —
Not listed Greenbrae California 94904 —
Not listed Loma Linda California 92354 —
Not listed Modesto California 95355 —
Not listed Montebello California 90640 —
Not listed Pomona California 91767 —
Not listed Sacramento California 95816 —
Not listed Norwich Connecticut 06360 —
Not listed Waterbury Connecticut 06708 —
Not listed Lake Worth Florida 33431 —
Not listed Miami Shores Florida 33179 —
Not listed New Port Richey Florida 34655 —
Not listed Ocala Florida 34474 —
Not listed Ocoee Florida 34761 —
Not listed Marietta Georgia 30060 —
Not listed Niles Illinois 60714 —
Not listed Paducah Kentucky 42002 —
Not listed Alexandria Louisiana 71301 —
Not listed Baltimore Maryland 21204 —
Not listed Baltimore Maryland 21237 —
Not listed Westminster Maryland 21157 —
Not listed Pittsfield Massachusetts 01201 —
Not listed Worcester Massachusetts 01608 —
Not listed Kalamazoo Michigan 49048 —
Not listed Duluth Minnesota 55805 —
Not listed Jefferson City Missouri 65109 —
Not listed Great Falls Montana 59405 —
Not listed Las Vegas Nevada 89109 —
Not listed Neptune City New Jersey 07754 —
Not listed Albuquerque New Mexico 87102 —
Not listed Albuquerque New Mexico 87131-5636 —
Not listed Santa Fe New Mexico 87505 —
Not listed Brooklyn New York 11219 —
Not listed Huntington Station New York 11746 —
Not listed Durham North Carolina 27710 —
Not listed Hickory North Carolina 28602 —
Not listed Canton Ohio 44718 —
Not listed Eugene Oregon 97401-8122 —
Not listed Ephrata Pennsylvania 17522 —
Not listed Langhorne Pennsylvania 19047 —
Not listed Philadelphia Pennsylvania 19102 —
Not listed Scranton Pennsylvania 18510 —
Not listed Charleston South Carolina 29403-5740 —
Not listed Charleston South Carolina 29406 —
Not listed Florence South Carolina 29506 —
Not listed Sumter South Carolina 29150 —
Not listed Chattanooga Tennessee 37404 —
Not listed Cookeville Tennessee 38501 —
Not listed Nashville Tennessee 37203 —
Not listed Amarillo Texas 79106 —
Not listed Arlington Texas 76014 —
Not listed Beaumont Texas 77702-1449 —
Not listed Bedford Texas 76022 —
Not listed Carrollton Texas 75010 —
Not listed Corpus Christi Texas 78412 —
Not listed Dallas Texas 75230 —
Not listed Dallas Texas 75231 —
Not listed Dallas Texas 75237 —
Not listed Fort Worth Texas 76104 —
Not listed Garland Texas 75042 —
Not listed Lewisville Texas 75067 —
Not listed Mesquite Texas 75150 —
Not listed Paris Texas 75460 —
Not listed Round Rock Texas 78681 —
Not listed San Antonio Texas 78229 —
Not listed Southlake Texas 76092 —
Not listed Sugarland Texas 77479 —
Not listed Waco Texas 76712 —
Not listed Webster Texas 77598-4420 —
Not listed Salt Lake City Utah 84106 —
Not listed Christiansburg Virginia 24073 —
Not listed Seattle Washington 98133 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00642603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 26, 2026 · Synced Nov 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00642603 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →